Press Releases Pulmatrix, Inc.

Equities

PULM

US74584P3010

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-14 pm EDT			5-day change	1st Jan Change
1.794 ^USD	+0.81%		-5.06%	-3.53%

May. 10	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 10	Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 13	AQ
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives	Jan. 09	AQ
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 10	AQ
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine	23-09-20	AQ
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-24	AQ
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update	23-08-11	AQ
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	23-07-12	AQ
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society	23-06-16	AQ
Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention	23-05-24	PR
Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update	23-05-15	AQ
Pulmatrix Supports World Asthma Day 2023	23-05-02	PR
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update	23-03-31	AQ
PULMATRIX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	23-03-30	AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-06	AQ
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma	23-02-06	PR
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-03	AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-01-25	AQ
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy Asthma and Immunology	23-01-24	AQ
PULMATRIX, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-01-11	AQ
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine for Acute Migraine	23-01-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Pulmatrix, Inc.

Equities

PULM

US74584P3010

Press Releases

Filters